Amer Zeidan, MBBS, MHS, associate professor of medicine, Yale University School of Medicine, joins the show to cover the latest exciting updates in the treatment landscapes for acute myeloid leukemia and myelodysplasia. The duo discuss the etiology of both malignancies, the intricacies of defining and diagnosing MDS, how patients become classified as either lower-risk or higher-risk MDS and the survival rates of both, concerns and consequences with iron overload during blood transfusions, and how transplant procedures have become safer for older patients. They then highlight the hot topics in MDS and AML as covered at the most recent ASH annual meeting.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
